ANI Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ANIP ANI Pharmaceuticals Inc
REG Regency Centers Corp
CHUY Chuy's Holdings Inc
HBUV Hubilu Venture Corporation
LMNL Liminal BioSciences Inc
NXTD NXT-ID Inc
RIOT Riot Blockchain Inc
HIHO Highway Holdings Ltd
CBAY Cymabay Therapeutics Inc
DTSS Datasea Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Closing Price
$29.86
Day's Change
0.25 (0.84%)
Bid
--
Ask
--
B/A Size
--
Day's High
29.86
Day's Low
28.42
Volume
(Average)
Volume:
88,887

10-day average volume:
96,367
88,887

Company Profile

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
1.81x
Price/Book (MRQ)
1.80x
Price/Cash Flow (TTM)
9.59x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

July 2020
Current Month
552.0K
Previous Month
542.6K
Percent of Float
5.76%
Days to Cover
5.9208 Days

Share Information

ANIP is in a share class of common stock
Float
9.6M
Shares Outstanding
12.3M
Institutions Holding Shares
198
84.61%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Robert E. BrownChmn.
  • Patrick D. WalshPres.
  • Stephen P. CareyCFO
  • Robert W. SchrepferSr.VP
  • James G. MarkenSr.VP

Address

Insider Trading

During the most recent quarter, 5K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.